Clinical Trial Update: Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating VM-1500 versus Efavirenz added to standard ART in HIV-1 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)
• VM-1500

Snippet

Sponsor: Viriom | Conditions: HIV-1-infection | Phase 2, Phase 3 | Status: COMPLETED